This site is intended for health professionals only

MS pill laquinimod shows efficacy at Phase 3

teaser

Another pill has shown efficacy at reducing relapses and progression of disability in patients with relapsing–remitting multiple sclerosis, a large Phase 3 study shows.

 

The oral medicine laquinimod, assessed in 1106 patients from 139 centres in 24 countries, reduced the number of relapses per year by an average of 23% and disability progression by 36%, the team reports in the New England Journal of Medicine. 

 

The trial assigned patients to receive laquinimod or placebo in a 1:1 ratio for 24 months. 

 

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

The “modest” reduction in relapse equated to a significant difference in annualised relapse rate of 0.3 in patients given laquinimod compared with 0.39 in those given placebo (p=0.002). 

 

Confirmed disability progression was detected in 11.1% of patients on laquinimod, compared with 15.7% of those assigned to receive placebo. 

 

The researchers, led by G Comi from Universita Vita-Salute San Raffaele in Milan, Italy, concluded: “In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.”

 

New England Journal of Medicine






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x